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Plant biotechnology in Argentina started at the end of the 1980s, leading to the
development of numerous research groups in public institutions and, a decade later,
to some local private initiatives. The numerous scientific and technological capacities
existing in the country allowed the early constitution in 1991 of a sound genetically
modified organisms biosafety regulatory system. The first commercial approvals began
in 1996, and to date, 59 events have obtained permits to be placed on the market,
however, only two have been developed locally by public-private partnerships. The
transgenic events developed at public institutions pursue different objectives in diverse
crops. However, once these events have been developed in laboratories, it is difficult
to move toward a possible commercial approval. In this work, we analyze several
reasons that could explain why local developments have not reached approvals
for commercialization, highlighting aspects related to the lack of strategic vision in
the institutions to focus resources on projects to develop biotechnological products.
Although progress has been made in generating regulatory rules adapted to research
institutes (such as the regulations for biosafety greenhouses and ways of presenting
applications), researchers still do not conceive regulatory science as a discipline. They
generally prefer not to be involved in the design of regulatory field trials or regulatory
issues related to the evaluation of events. In that sense, some of the aspects considered
a regulatory affairs platform for the public scientific system and the reinforcement of
laboratories that perform tests required under the Argentine regulation.
Keywords: regulatory system, GMO biosafety, Argentine regulation, local developments, commercial approval
BRIEF HISTORY OF BIOTECHNOLOGY IN ARGENTINA
Plant biotechnology in Argentina started at the end of the 1980s, leading to the development
of numerous research groups in public institutions and, a decade later, to some local private
initiatives. However, a prospective analysis of the local capacities of Argentina for the development
and marketing of events derived from biotechnology would have led to a much more optimistic
scenario than the one observed nowadays. Argentina’s experience with plant biotechnology
began with pioneers such as Esteban Hopp, at the National Institute of Agricultural Technology
(INTA), and Alejandro Mentaberry, at the National Scientific and Technical Research Council
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(CONICET), in the late 1980s, both of whom mentored the
subsequent generations of specialized academics in the area.
Farmers in Argentina have always rapidly adopted new
developments and technologies. Indeed, Argentine fields
currently have more than 24.9 million hectares of GM crops, 19.2
of which are of soybean (almost 100%), 5.5 of maize (96%), and
0.3 of cotton (almost 100%). These data indicate that farmers are
not reluctant to adopt these crops, the vast majority of which are
developed abroad (ISAAA, 2018).
In 1991, the National Advisory Commission on Agricultural
Biotechnology (known by the Spanish acronym, CONABIA),
whose function consists of reviewing the safety assessments of
biotechnology events, was formed. CONABIA is still operative
today1 and its members include, among others, specialists
in the fields of genetics, plant physiology, and agronomy.
A significant aspect of the Argentine regulatory system is that
it is widely recognized as being a structure that has remained
“uncontaminated” by bureaucratic history, where scientific and
technical credibility and enforceability prevail, which is critical
when dealing with a sensitive issue for society, such as GM crops
(Vicién and Trigo, 2017).
Since its creation, CONABIA has been instrumental to the
successful evaluation of more than 50 different (single and
stacked) events. Thanks to its outstanding academic members
and excellent track record in the field, in 2014, CONABIA was
recognized as a Reference Center for the Biosafety of genetically
modified organisms (GMOs) by the FAO. Considering these
facts, Argentina should have been much more successful in the
deregulation of its local biotechnological events. However, only
two out of the more than fifty events that have been approved for
commercialization were developed locally.
The regulatory process in Argentina is established in
Resolution 763/2011 issued by the Ministry of Agriculture. This
Resolution establishes a procedure divided into three steps: (i)
an environmental assessment performed by CONABIA, (ii) a
food and feed safety evaluation performed by the National Agri-
Food Health and Quality Service (known as SENASA, by its
Spanish acronym), and (iii) an evaluation of its impact on the
agricultural market. Once each step is completed, a Decision
Document is drafted, which must be favorable for the event
to be approved. The procedure is the same for both local
and imported events. Most of the events that have passed
through the regulatory process have been developed by private
companies, mostly from the Northern Hemisphere2 (Figure 1:
events approved in Argentina).
Table 1 shows the two national events approved for
commercialization that have completed all the steps of the
regulatory process: the abiotic stress-resistant and herbicide-
tolerant Soybean HB4, developed by the local business company
INDEAR (a public and private partnership formed by CONICET
and the enterprise BIOCERES), and the virus Y-resistant Potato
PVY, developed by CONICET and achieved by the company
Sidus-Tecnoplant, a public-private collaboration.
1https://www.argentina.gob.ar/convocatoria-conabia
2https://www.argentina.gob.ar/ogm-comerciales
In 2015, another event was almost approved for
commercialization: sugarcane with glyphosate resistance.
This event passed the environmental and food and feed safety
assessments, but failed to pass the agricultural market impact
evaluation, possibly because of the negative public perception of
sugarcane stakeholders3. The developments of sugarcane varieties
are carried out by both public and private sector institutions.
Wheat HB4, another local development by INDEAR, which
has drought resistance, is currently undergoing the evaluation
and has already achieved approval from both CONABIA and
SENASA, but it is still awaiting the final decision from the
Agricultural Markets Office4. In that sense, beyond regulations,
another aspect of the Argentine system that has to be considered
is the internalization of potential trade problems, which is based
on its position as a net exporting country. This is generally one of
the main causes for the delay in approvals, since the government
weighs the consequences of any new products on the Argentinian
market (Vicién, 2012).
Regarding the remaining local developments listed in Table 1
(a list that may not be exhaustive), many have not gone beyond
the laboratory step, others have only completed the greenhouse
step, and very few have been evaluated in the field. This situation
inevitably raises questions regarding the difficulties faced by local
developments when looking for deregulation.
Other countries in the region are in similar situations
regarding the adoption of biotechnology and are working to
establish their deregulation procedures. FAO asked CONABIA
to assist other countries that were establishing their regulatory
frameworks, a program that is proving successful in training
specialists on how to perform risk assessment for GM crops.
While Argentina’s regulatory system serves as a reference for
many countries, it is important to note that the system does
not appear to support local developments. Fortunately, there
are exceptions in the region, such as the virus-resistant beans
obtained by the Brazilian Agricultural Research Corporation
(EMBRAPA by its acronym in Portuguese), developed by
Francisco de Aragao’s Group (Faria et al., 2016). So far, this
has been the only case in which an entirely public development
achieved approval by the Brazilian National Technical Biosafety
Commission (CTNBIO by its acronym in Portuguese), having
also completed every assay required in publicly funded labs5.
Over the last 30 years, the scientific-technological system in
Argentina, composed of public institutions and universities, has
led to the development of many GM crop events, such as potato,
alfalfa, wheat, maize, sunflower, sugarcane, soybean, lettuce, and
cotton (Table 1). These were achieved mostly through funding
from institutions such as INTA, CONICET, Universities, and the
National Agency for Scientific-Technical Promotion (ANPCyT
by its acronym in Spanish) and other public sources. The projects
are financially and economically evaluated taking into account
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FIGURE 1 | Approved biotechnological events in Argentina. Graphics made based on data published on the site https://www.argentina.gob.ar/ogm-comerciales.
(A) number of events by crop; (B) number of events by trait; (C) number of events approved by type of developer; (D) cases of gene editing consulted (A. Whelan,
personal communication).
and varietal registration), potential benefits for farmers and
for the value chain, prospective on possible markets (both
internal and external), and relative sizes and possible degree
of adoption. After obtaining the desired prototypes for each
laboratory event, developments only reach the stage of growth
chamber or greenhouse trials. However, once they are stabilized
and multiplied, in many cases, there is not enough funding to
advance to field trials and complete the remaining steps of the
regulatory procedure.
NEW NORMS FOR NEW TECHNIQUES
The regulatory framework has been recently updated in
Argentina. The country pioneered the development of
regulations for the so-called “new breeding techniques” (NBTs),
as specified in Resolution No. 173 of 2015 from the Ministry
of Agriculture (Whelan and Lema, 2015) and also present in
the updated version from the same Ministry (Resolution No.
36, 2019). This Resolution states that, to be considered as a
“Genetically Modified Organism,” the product must possess a
novel combination of genetic material obtained through the
use of modern biotechnology in accordance with the definition
from the Cartagena Protocol on Biosafety (Secretariat of the
Convention on Biological Diversity [SCBD], 2000). Under
these guidelines, the applicants must describe in detail the
intended modifications and the way they plan to obtain them
in an “Instance of Prior Consultation” (ICP by its Spanish
acronym). CONABIA will send an answer to the applicant within
60 days to determine the regulatory status of the product. This
procedure allows researchers to know whether their product will
be considered as a GMO or not, even before starting laboratory
work. The procedure has served as an incentive for private
companies and public institutions to undertake new projects,
with knowledge at the outset that costly regulatory testing will
not be necessary. To date, most of the inquiries received by
the authorities have come from locally developed products
(Lema, 2019).
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TABLE 1 | List of biotechnological developments in Argentina.











Virus PVX-PLRV × ×
Virus PVY × × × × Public/private
Wheat Nutrition facts × Public
Abiotic stress × ×
Abiotic stress × × × Private
Alfalfa Herbicide × × Public
Abiotic stress × ×
Orange Virus × × Public
Maize Abiotic stress × × Public
Abiotic stress × × Private
Cotton Boll weavil × Public
Sugarcane Virus × × Private
Herbicide × × ×
Peach Quality × Public
Tomato Abiotic stress × Public
Leaf area ×
Nutrition fatcts ×
Lettuce Virus × Public
Fungal ×
Sunflower Fungal × Public
Grape Abiotic and abiotic stress × Public
Soybean Herbicide × × × × Public/private
Abiotic stress × × × ×
Paspalum Abiotic stress × Public
Chloris gayana Abiotic stress × Public
Fescue Herbicide × × Public
Gene editing, one of the NBTs discussed above, is one
promising new biotechnological approach to improve crops
that is considered more precise and can avoid the insertion
of unnecessary genes. Crops modified using gene editing may
be more easily adopted because products require a simpler
regulatory procedure (Jones, 2015; Georges and Ray, 2017). The
procedure described in Resolution No. 173/15 is streamlined for
products derived from gene editing but it would still be subject to
regulation, given that any product derived from the application of
biotechnology is still regulated until it is determined that it does
not contain stable DNA insertions. Before then, all associated
material must be handled in contained and confined conditions.
DIALOGUE BETWEEN RESEARCHERS
AND PUBLIC REGULATORS IN
ARGENTINA
In 2014, given difficulties faced by developers in
Argentina, REDBIO (a non-profit organization bringing
together plant biotechnology labs across Argentina)
held two workshops to debate and share ideas
regarding the prevailing situation. In that sense,
two official statements were drafted and addressed
to the authorities responsible for regulation at the
Ministry of Agriculture.
In these workshops, the various problems faced by
researchers regarding the current regulatory system
in Argentina were considered. The conclusions
are listed below.
Regarding Policies
– General lack of State support for most research
information and commercialization of GM events.
– Insufficient sources of resources and State funding to go
through the trials required for deregulation.
– The non-existence of formal State structures to facilitate,
organize, and present regulatory data to the relevant
agencies.
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Regarding the Regulatory Process
For Developers
– They are often unaware of the general regulatory process.
– No guidelines specify how developers should start with
the regulatory process.
– The processes and steps to complete, as well as the initial
data required, are unclear.
– Many developers are not up to date on the resolutions
setting out the process.
For the Authorities
– There is no coordination between the agencies and offices
involved in the three steps of assessment.
– There is an overlapping of the information required
from each agency.
– Requirements and criteria are often excessive.
Regulatory Data Generation
– There is a need for a complete diagnosis of the available
infrastructure and capabilities of the national science and
technology system.
– There is insufficient funding for regulatory studies.
– There is insufficient information and training on the
steps to follow in the regulatory process.
– There is a need for a definition of national and
international harmonized quality standards in confined
field trials.
It has to be highlighted that researchers in public institutions
such as INTA have always worked collaboratively with breeders,
who have extensive experience in intellectual property
issues, varietal registration, and the respective procedures
established by the National Institute of Seeds (INASE by its
acronym in Spanish).
To respond to the needs raised in the 2014 workshops, two
trainings for researchers were organized by public institutions
such as INTA and CONICET and NGOs such as Redbio,
ILSI, and Argenbio. Researchers from all plant biotechnology
development centers of Argentina participated in them and
their projects were analyzed concerning how regulatory studies
should be addressed.
The authorities of the Ministry of Agriculture and the Ministry
of Science and Technology who participated in these workshops
and acknowledged the problems discussed there created a
competitive financial funding program for regulatory studies.
This program was organized by ANPCyT in 2015 and was called
FONREBIO (Biotechnological Products’ Regulation Funding)6.
This funding was initially conceived as a non-reimbursable
subsidy for public institutions. However, by the time of its
issuance and implementation at the end of 2015, it became a sort
of reimbursable loan, which required the approval for a private
source of partial backing or commitment for quick insertion
into the market. It was announced as a loan of ARS 20 million
(USD 1 million at that time), consisting of up to 80% of the
project’s total cost, with at least 20% of its funding coming from
6http://www.mincyt.gob.ar/convocatoria/fonrebio-11901
private sources. This restricted the chances of projects coming
from public institutions and forced these institutions to seek
support from companies interested in investing in the projects.
Furthermore, the chances for a project to advance were tied to its
intrinsic potential for commercial success.
Similarly, INTA established an internal contest for the
use of royalty funds owned by the institution (known as
“Fondos de valorización tecnológica”). The funding was meant to
promote the insertion of products developed by INTA, including
biotech events, into the market. To apply, the development
must be commercially viable and easily adopted by producers,
which again limits the availability of funding to economically
competitive developments only. At the beginning of 2018, the
funding consisted of ARS 20 million (USD 1 million back then
but only USD 300 thousand nowadays due to the devaluation
of the Argentine peso) directed at projects of many different
origins, including biotech events. The amount offered quickly
proved to be insufficient. Once again, an initiative to boost local
developments ended up being inadequate to achieve that goal.
As previously mentioned, local projects can have many
different goals. Some of them focus on productivity, which gives
them better chances to compete for funding to pay for regulatory
studies successfully, whereas others are meant to enhance quality,
or are directed at small producers or family farms, which leaves
their chances to acquire private backing limited or completely
cut off. This means that they end up being unable to pay for the
cost of the regulatory process, thus keeping the product from ever
reaching the market.
Regarding the costs of the deregulation process, some
estimates indicate that it is roughly ten times that of the
development itself. These estimates include the costs of gene
discovery together with those of the deregulation in various
countries, which is partly why the total amount needed varies so
much (Kent, 2004; Falck-Zepeda et al., 2012; Prado et al., 2014).
Variation in cost depends on the number of countries where it
is filed and the nature of the studies required according to the
approval policies of each country. Even though in most cases the
necessary studies to achieve approval for commercialization are
well established, the amount of money needed to complete them
is up for debate, and can be high enough for small businesses
or public institutions to abandon or delay the marketing of
locally potentially valuable products. Currently, mainly private
multinational companies can afford the regulatory burden of
approvals in different countries.
Another factor that makes this process even more expensive
is the quality certification needed for the data obtained in
the regulatory studies. For the EU, the data required must be
GLP (Good Laboratory Practices) certified. This certification
is handled by the Argentine Accreditation Body (OAA by its
Spanish acronym). So far, only a few institutions have been
able to achieve this certification, which is expensive. SENASA
and CONABIA do not currently require this certification but
procedures and data integrity are thoroughly examined.
The current state of event approval across the globe must also
be taken into consideration. To avoid problems with imports
and exports, the approval of a single event is often requested in
more than one country at the same time (for example, a maize
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event may be presented simultaneously in the United States,
European Union, Brazil, Argentina, Colombia, and Paraguay).
Every country added to that list results in additional costs and
resources. To facilitate the process for their products, many
international companies engage their own Regulatory Affairs
Departments. This practice allows an efficient organization of
both human and financial resources. Until now, there is nothing
similar in public institutions.
Based on all the above, the following questions can be posed:
Can a local project achieve deregulation in the country? Can it
achieve the same acceptable standards for safety as a previously
approved privately funded one? Can locally funded projects
afford de-regulation in other countries?
THE PARADOX
As a result of the foregoing, public institutions find it almost
impossible to raise funds for the deregulation process, the
cost of which exceeds any funding that may be obtained.
Thus, a paradox is established, whereby products derived from
plant biotechnology, such as GMOs, are developed to address
production problems and improve crop quality in ways that
conventional breeding cannot achieve, and yet, for these products
to be approved and thus be used by farmers, they must meet
the criteria set by regulatory authorities in each country where
they are expected to be commercialized. The required regulatory
studies are extraordinarily expensive and can only be paid for if
the institution or company where the product was developed has
the necessary funding.
Consequently, only private developments with sufficient
funding and adequate resource management are able to pay
for the required studies and their certification. Therefore, the
only products to ever reach the market are those derived from
private initiatives of transnational firms. Developments seeking
to solve problems for local production or small farmers are
seldom given a chance to reach approval, as they are less attractive
for large companies because markets and sales are smaller in
size. Furthermore, even when they are granted approval, after
much effort and search for company help, as it happened
with PVY-resistant potato, developers may find obstacles
to commercialization because of public perception barriers.
Another controversial case is that of wheat HB4 R©, which was
approved by two out of three agencies (CONABIA and SENASA)
but rejected by the agricultural market evaluation, because of the
unfavorable public perception of the crop’s value chain.
In this context, further questions that can be posed include:
How can this problem be solved? Which institutional paths can
be explored? What should be proposed?
As mentioned before, private multinational companies have
regulatory affairs departments, composed of professionals
in charge of designing the studies, managing agency
permits, performing field trials, and conducting follow-up of
developments to comply with regulatory criteria all over the
world. Public institutions do not have anything like that. A good
start for public policies meant to help the development of local
biotechnology through the organization of human and financial
resources would be the creation of a government agency for
GMO regulatory affairs as a shared platform to make the process
faster, easier, and more efficient. Local researchers and developers
must also consider starting a dialogue with every participant
in the value chain, including producers and coordinators of
crop breeding programs, from the very beginning of the initial
development (the original idea). These considerations can be
applied to GMOs, as well as to products obtained through the
application of gene editing and other new tools of biotechnology.
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